Electromyographic activity of the diaphragm during neostigmine or sugammadex-enhanced recovery after neuromuscular blockade with rocuronium: a randomised controlled study in healthy volunteers
- PMID: 25111539
- DOI: 10.1097/EJA.0000000000000140
Electromyographic activity of the diaphragm during neostigmine or sugammadex-enhanced recovery after neuromuscular blockade with rocuronium: a randomised controlled study in healthy volunteers
Abstract
Background: The use of neuromuscular blocking agents has been associated with severe postoperative respiratory morbidity. Complications can be attributed to inadequate reversal, and reversal agents may themselves have adverse effects.
Objective: To compare the electromyographic activity of the diaphragm (EMGdi) during recovery from neuromuscular blockade using neostigmine and sugammadex. The hypothesis was that there would be better neuromuscular coupling of the diaphragm when sugammadex was used.
Design: A randomised, controlled, parallel-group, single-centre, double-blinded study.
Setting: District general hospital in Belgium.
Participants: Twelve healthy male volunteers.
Interventions: Individuals were anaesthetised with propofol and remifentanil. After rocuronium 0.6 mg kg, a transoesophageal electromyography (EMG) recorder was inserted. For reversal of neuromuscular blockade, volunteers received sugammadex 2 mg kg (n = 6) or neostigmine 70 μg kg (n = 6).
Main outcome measures: EMGdi, airway pressure and flow were continuously measured during weaning from the ventilator until tracheal extubation. Arterial blood gas samples were obtained for PaO2 and PaCO2 analysis at the first spontaneous breathing attempt and after tracheal extubation.
Results: During weaning, 560 breaths were retained for analysis. The median (95% CI) peak EMGdi was 1.1 (0.9 to 1.5) μV in the neostigmine group and 1.6 (1.3 to 1.9) μV in the sugammadex group (P < 0.001). Individuals in the neostigmine group had 125 of 228 (55%) breaths with associated EMGdi at least 1 μV vs. 220 of 332 (66%) breaths in the sugammadex group (P = 0.008). The median (95% CI) tidal volume was 287 (256 to 335) ml after neostigmine and 359 (313 to 398) ml after sugammadex (P = 0.013). The median (95% CI) PaO2 immediately after extubation was 30.5 (22.8 to 37.1) kPa after sugammadex vs. 20.7 (12.9 to 27.5) kPa after neostigmine (P = 0.03).
Conclusion: EMGdi, tidal volume and PaO2 following tracheal extubation were increased after sugammadex compared with neostigmine, reflecting diaphragm-driven inspiration after sugammadex administration. Sugammadex may free more diaphragmatic acetylcholine receptors than neostigmine, which has an indirect effect.
Trial registration: EudraCT ref: 2013-002078-30.
Similar articles
-
Diaphragmatic and intercostal electromyographic activity during neostigmine, sugammadex and neostigmine-sugammadex-enhanced recovery after neuromuscular blockade: A randomised controlled volunteer study.Eur J Anaesthesiol. 2017 Jan;34(1):8-15. doi: 10.1097/EJA.0000000000000543. Eur J Anaesthesiol. 2017. PMID: 27902641 Clinical Trial.
-
Sugammadex reversal of rocuronium-induced neuromuscular blockade: a comparison with neostigmine-glycopyrrolate and edrophonium-atropine.Anesth Analg. 2007 Mar;104(3):569-74. doi: 10.1213/01.ane.0000248224.42707.48. Anesth Analg. 2007. PMID: 17312210 Clinical Trial.
-
Low-Dose or High-Dose Rocuronium Reversed with Neostigmine or Sugammadex for Cesarean Delivery Anesthesia: A Randomized Controlled Noninferiority Trial of Time to Tracheal Intubation and Extubation.Anesth Analg. 2016 May;122(5):1536-45. doi: 10.1213/ANE.0000000000001197. Anesth Analg. 2016. PMID: 26974018 Clinical Trial.
-
Efficacy and safety of sugammadex compared to neostigmine for reversal of neuromuscular blockade: a meta-analysis of randomized controlled trials.J Clin Anesth. 2016 Dec;35:1-12. doi: 10.1016/j.jclinane.2016.06.018. Epub 2016 Aug 4. J Clin Anesth. 2016. PMID: 27871504 Review.
-
Profile of sugammadex for reversal of neuromuscular blockade in the elderly: current perspectives.Clin Interv Aging. 2017 Dec 22;13:13-24. doi: 10.2147/CIA.S134108. eCollection 2018. Clin Interv Aging. 2017. PMID: 29317806 Free PMC article. Review.
Cited by
-
Respiratory muscle activity after spontaneous, neostigmine- or sugammadex-enhanced recovery of neuromuscular blockade: a double blind prospective randomized controlled trial.BMC Anesthesiol. 2019 Oct 19;19(1):187. doi: 10.1186/s12871-019-0863-y. BMC Anesthesiol. 2019. PMID: 31629404 Free PMC article. Clinical Trial.
-
Quality of Recovery after Laparoscopic Cholecystectomy Following Neuromuscular Blockade Reversal with Neostigmine or Sugammadex: A Prospective, Randomized, Controlled Trial.J Clin Med. 2021 Mar 1;10(5):938. doi: 10.3390/jcm10050938. J Clin Med. 2021. PMID: 33804329 Free PMC article.
-
Sugammadex: Appropriate Use in the Context of Budgetary Constraints.Curr Anesthesiol Rep. 2018;8(2):178-185. doi: 10.1007/s40140-018-0265-6. Epub 2018 Mar 20. Curr Anesthesiol Rep. 2018. PMID: 29904285 Free PMC article. Review.
-
Recent advances in neuromuscular block during anesthesia.F1000Res. 2018 Feb 9;7:167. doi: 10.12688/f1000research.13169.1. eCollection 2018. F1000Res. 2018. PMID: 29497496 Free PMC article. Review.
-
Efficacy and safety of sugammadex versus neostigmine in reversing neuromuscular blockade in adults.Cochrane Database Syst Rev. 2017 Aug 14;8(8):CD012763. doi: 10.1002/14651858.CD012763. Cochrane Database Syst Rev. 2017. PMID: 28806470 Free PMC article.
Publication types
MeSH terms
Substances
Associated data
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical